Durham, NC – According to filings with the U.S. Securities and Exchange Commission, Ten63 Therapeutics is raising $2,149,981.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Marcel Frenkel played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Ten63 Therapeutics

Our platform, COPPER, leverages our proprietary AI and state-of-the-art physical models to explore an unprecedentedly large chemical space, allowing us to discover new therapeutics to targets previously believed undruggable. Our mission is to improve human health by developing potent therapeutics against medically validated, yet undruggable targets.

To learn more about Ten63 Therapeutics, visit http://www.ten63tx.com/

Contact:
Marcel Frenkel, Chief Executive Officer
919-263-4218
https://www.linkedin.com/in/marcelfrenkel/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved